Aptevo Therapeutics Inc.
$5.21
▲
0.97%
2026-04-21 05:21:01
aptevotherapeutics.com
NCM: APVO
Explore Aptevo Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.24 M
Current Price
$5.21
52W High / Low
$486 / $3.8
Stock P/E
—
Book Value
$17.42
Dividend Yield
—
ROCE
-124.44%
ROE
-2.35%
Face Value
—
EPS
$-87.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
33
Beta
1.51
Debt / Equity
26.63
Current Ratio
3.81
Quick Ratio
3.82
Forward P/E
-0.24
Price / Sales
—
Enterprise Value
$-11.74 M
EV / EBITDA
0.45
EV / Revenue
—
Rating
Strong Buy
Target Price
$21
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 2. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 3. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 4. | Savara Inc. | $5.61 | — | $1.15 B | — | -52.68% | -63.45% | $7 / $1.89 | $0.8 |
| 5. | CollPlant Biotechnologies Ltd. | $0.37 | — | $5.15 M | — | -141.54% | -1.18% | $4.98 / $0.27 | $0.47 |
| 6. | Zura Bio Limited | $5.37 | — | $491.42 M | — | -74.11% | -52.49% | $7.44 / $0.98 | $1.38 |
| 7. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6 M | -7.61 M | -6.23 M | -6.48 M | -6.38 M | — |
| Net Profit | -5.81 M | -7.55 M | -6.2 M | -6.41 M | -6.31 M | — |
| EPS in Rs | -4.91 | -6.39 | -5.25 | -5.42 | -5.34 | -3,985.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 3.11 M |
| Operating Profit | -26.31 M | -24.6 M | -28.88 M | -28.64 M |
| Net Profit | -25.97 M | -24.13 M | -17.41 M | 8.03 M |
| EPS in Rs | -21.97 | -20.42 | -14.73 | 6.79 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 27.19 M | 15.59 M | 24.84 M | 34.22 M |
| Total Liabilities | 9.81 M | 10.84 M | 12.62 M | 16.24 M |
| Equity | 17.38 M | 4.75 M | 12.22 M | 17.97 M |
| Current Assets | 23.08 M | 10.66 M | 19.07 M | 27.45 M |
| Current Liabilities | 6.05 M | 6.21 M | 7.22 M | 8.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -25.59 M | -23.79 M | -11.73 M | -21.02 M |
| Investing CF | 0 M | 0 M | 0 M | -0.03 M |
| Financing CF | 38.5 M | 15.6 M | 6 M | -2.62 M |
| Free CF | -25.59 M | -23.79 M | -11.73 M | -21.05 M |
| Capex | — | — | — | -0.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -38.59% | -316.91% | — | — |
| Profit Margin % | — | — | 257.77% | — |
| Operating Margin % | — | — | -919.75% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -890.82% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-30 | 1:0.0555556 |
| 2025-05-27 | 1:0.05 |
| 2024-12-04 | 1:0.027027 |
| 2024-03-06 | 1:0.0227273 |